课题基金 / 基金详情

Phosphodiesterases Restrict Spontaneous Beating of Cardiac Pacemaker Cells

Phosphodiesterases Restrict Spontaneous Beating of Cardiac Pacemaker Cells
磷酸二酯酶限制心脏起搏细胞的自发搏动
批准号:
7963903
负责人:
Edward Lakatta
金额:
$22.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Edward Lakatta的其他基金

相似基金

相关文献

中文摘要
翻译
兔窦房结细胞(SANC)的自发性搏动由cAMP介导的依赖蛋白激酶A的局部肌膜下兰尼定受体(LCRs)控制。LCRs激活内向Na+/Ca~(2+)交换电流,使舒张末期除极速率增加,从而使自发搏动频率增加。SANC的基础cAMP升高,提示磷酸二酯酶(PDE)对cAMP的降解可能较低。令人惊讶的是,用广谱PDE抑制剂3-异丁基甲基黄嘌呤(IBMX)完全抑制PDE活性后,cAMP水平增加了9倍,cAMP介导的蛋白激酶依赖的磷蛋白磷酸化增加了一倍,SANC的放电频率增加了55%,表明SANC中PDE的基础活性很高。特异性PDE1to-5抑制剂的比较表明,PDE3的特异性抑制剂米力农使自发放电增加47%(其他作用很小),使L型钙电流(ICa,L)的幅度增加46%,表明PDE3是基础状态下的主要成分活性的PDE。PDE抑制对自发放电的依赖依赖于肌膜下LCR,即抑制PDE可增加LCR的幅度和大小,缩短LCR周期,导致LCR钙释放提前和延长,Na+/Ca~(2+)交换电流和放电频率增加。当Ryanodine受体被Ryanodine阻断时,IBMX和米力农都不能放大LCRs,加快舒张期去极化速率,也不能增加SANC放电率,尽管保留PDE抑制了ICa的幅度增加,L。因此,基础成分PDE的激活为降低cAMP、限制cAMP介导的蛋白激酶A依赖的舒张期Ryanodine受体钙释放增加、限制自发搏动频率提供了一种新的、强大的机制。为了研究PDE抑制如何控制SR钙再充盈和LCR周期,我们比较了对照组和PDE抑制后SR钙再充盈的动力学。磷酸化蛋白(PLB)被用来作为SR泵送速率的指标,SR再充盈是通过AP启动的整体胞浆Ca~(2+)瞬变(T-90)衰减到90%的时间来估计的。广谱磷酸二酯酶抑制剂(IBMX)、特异性磷酸二酯酶-3抑制剂(米力农)或特异性PKA抑制肽(PKI)对PLB的分级磷酸化与T-90的比例变化平行。T-90和LCR周期的伴随变化与自发周期长度的变化高度相关。因此,抑制PDE活性增加cAMP介导的PKA依赖的磷酸化,加快肌浆网钙充盈速率,缩短LCR周期和钙时钟,增加SANC的自发搏动频率。
英文摘要
Spontaneous beating of rabbit sinoatrial node cells (SANCs) is controlled by cAMP-mediated, protein kinase Adependent local subsarcolemmal ryanodine receptor Ca2+ releases (LCRs). LCRs activated an inward Na+/ Ca2+ exchange current that increases the terminal diastolic depolarization rate and, therefore, the spontaneous SANC beating rate. Basal cAMP in SANCs is elevated, suggesting that cAMP degradation by phosphodiesterases (PDEs) may be low. Surprisingly, total suppression of PDE activity with a broad-spectrum PDE inhibitor, 3-isobutylmethylxanthine (IBMX), produced a 9-fold increase in the cAMP level, doubled cAMP-mediated, protein kinase Adependent phospholamban phosphorylation, and increased SANC firing rate by ≈55%, indicating a high basal activity of PDEs in SANCs. A comparison of specific PDE1 to -5 inhibitors revealed that the specific PDE3 inhibitor, milrinone, accelerated spontaneous firing by ≈47% (effects of others were minor) and increased amplitude of L-type Ca2+ current (ICa,L) by ≈46%, indicating that PDE3 was the major constitutively active PDE in the basal state. PDE-dependent control of the spontaneous SANC firing was critically dependent on subsarcolemmal LCRs, ie, PDE inhibition increased LCR amplitude and size and decreased LCR period, leading to earlier and augmented LCR Ca2+ release, Na+/ Ca2+ exchange current, and an increase in the firing rate. When ryanodine receptors were disabled by ryanodine, neither IBMX nor milrinone was able to amplify LCRs, accelerate diastolic depolarization rate, or increase the SANC firing rate, despite preserved PDE inhibitioninduced augmentation of ICa,L amplitude. Thus, basal constitutive PDE activation provides a novel and powerful mechanism to decrease cAMP, limit cAMP-mediated, protein kinase Adependent increase of diastolic ryanodine receptor Ca2+ release, and restrict the spontaneous SANC beating rate. To study how PDE inhibition controls the SR Ca2+ refilling and LCR period we compared kinetics of SR Ca2+ refilling in control and after PDE inhibition. Phosphorylation of phospholamban (PLB) has been used as index of SR pumping rate and SR refilling was estimated by the time to 90% decay of the AP-initiated global cytosolic Ca2+ transient (T-90). Graded PLB phosphorylation by a broad-spectrum phosphodiesterase inhibitor (IBMX), specific phosphodiesterase-3 inhibitor (milrinone), or by specific PKA inhibitor peptide (PKI) were paralleled by proportional changes in T-90. Concomitant changes in T-90 and LCR period were highly correlated with changes in the spontaneous cycle length. Thus, suppression of PDE activity increases cAMP-mediated PKA-dependent phosphorylation, accelerates the SR Ca2+ refilling rate, decreases the LCR period, Ca2+ clock, and increases spontaneous beating rate of SANC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PUFA Dietary Intervention for Heart Rate
  • 批准号:
    8335786
  • 项目类别:
  • 资助金额:
    $25.83万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Decreased pacemaker activity in aged sinoatrial node
  • 批准号:
    8335801
  • 项目类别:
  • 资助金额:
    $11.03万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
  • 批准号:
    8552494
  • 项目类别:
  • 资助金额:
    $12.3万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
  • 批准号:
    9147229
  • 项目类别:
  • 资助金额:
    $15.43万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
库否细胞(Kupffer cells)受体PirB/LILRB2在非酒精性脂肪性肝炎中的作用及机制研究
  • 批准号:
    82470907
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2024
  • 负责人:
    余学锋
  • 依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位: